These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27875665)

  • 41. Eyes on new product development.
    Novack GD
    J Ocul Pharmacol Ther; 2015 Mar; 31(2):61-2. PubMed ID: 25715098
    [No Abstract]   [Full Text] [Related]  

  • 42. Eyes on new product development.
    Novack GD
    J Ocul Pharmacol Ther; 2013 May; 29(4):379. PubMed ID: 23627907
    [No Abstract]   [Full Text] [Related]  

  • 43. Eyes on New Product Development.
    Novack GD
    J Ocul Pharmacol Ther; 2015 Dec; 31(10):587-8. PubMed ID: 26562091
    [No Abstract]   [Full Text] [Related]  

  • 44. Eyes on new product development.
    Novack GD
    J Ocul Pharmacol Ther; 2014 Aug; 30(6):445-6. PubMed ID: 24978906
    [No Abstract]   [Full Text] [Related]  

  • 45. Keep your eyes open: challenges and opportunities in ophthalmic therapeutics.
    Wang S
    Future Med Chem; 2012 Nov; 4(17):2119-21. PubMed ID: 23190095
    [No Abstract]   [Full Text] [Related]  

  • 46. A New Vision for the Eye: Unmet Ocular Drug Delivery Needs.
    Rivers HM; Ray Chaudhuri S; Shah JC; Mittal S
    Pharm Res; 2015 Sep; 32(9):2814-23. PubMed ID: 26055402
    [No Abstract]   [Full Text] [Related]  

  • 47. Eyes on new product development.
    Novack GD
    J Ocul Pharmacol Ther; 2015 Jun; 31(5):257. PubMed ID: 26039112
    [No Abstract]   [Full Text] [Related]  

  • 48. Eyes on New Product Development.
    Novack GD
    J Ocul Pharmacol Ther; 2015 Oct; 31(8):445-6. PubMed ID: 26367793
    [No Abstract]   [Full Text] [Related]  

  • 49. Targeted Drug Delivery Within the Eye Through the Suprachoroidal Space.
    Patel SR; Prausnitz MR
    J Ocul Pharmacol Ther; 2016 Dec; 32(10):640-641. PubMed ID: 27849435
    [No Abstract]   [Full Text] [Related]  

  • 50. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases.
    Choonara YE; Pillay V; Danckwerts MP; Carmichael TR; du Toit LC
    J Pharm Sci; 2010 May; 99(5):2219-39. PubMed ID: 19894268
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Eyes on New Product Development: Preclinical Research.
    Novack GD
    J Ocul Pharmacol Ther; 2018; 34(1-2):4-6. PubMed ID: 29377737
    [No Abstract]   [Full Text] [Related]  

  • 52. Eyes on New Product Development.
    Novack GD
    J Ocul Pharmacol Ther; 2015; 31(6):311-3. PubMed ID: 26076427
    [No Abstract]   [Full Text] [Related]  

  • 53. [Current status of clinical trials of novel agents for multiple myeloma].
    Kuroda J
    Rinsho Ketsueki; 2014 Oct; 55(10):2005-15. PubMed ID: 25297766
    [No Abstract]   [Full Text] [Related]  

  • 54. [New trends in ocular drug delivery].
    Saettone MF
    Arch Soc Esp Oftalmol; 2003 Feb; 78(2):67-9. PubMed ID: 12647246
    [No Abstract]   [Full Text] [Related]  

  • 55. Current and future ophthalmic drug delivery systems. A shift to the posterior segment.
    Del Amo EM; Urtti A
    Drug Discov Today; 2008 Feb; 13(3-4):135-43. PubMed ID: 18275911
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Eyes on New Product Development.
    Novack GD
    J Ocul Pharmacol Ther; 2019 Sep; 35(7):377-378. PubMed ID: 31329497
    [No Abstract]   [Full Text] [Related]  

  • 57. Eyes on New Product Development.
    Novack GD
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):499-500. PubMed ID: 28753094
    [No Abstract]   [Full Text] [Related]  

  • 58. Chemistry-enabled drug delivery (prodrugs): recent progress and challenges.
    Clas SD; Sanchez RI; Nofsinger R
    Drug Discov Today; 2014 Jan; 19(1):79-87. PubMed ID: 23993918
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Eyes on New Product Development.
    Novack GD
    J Ocul Pharmacol Ther; 2018; 34(6):427-428. PubMed ID: 29927692
    [No Abstract]   [Full Text] [Related]  

  • 60. Hot topic: updates on therapeutic approaches to inflammatory skin diseases: from molecular targets to drug development. Part I.
    Korkina L; Pastore S
    Curr Drug Metab; 2010 Mar; 11(3):208-9. PubMed ID: 20443778
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.